Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Company testing three existing COVID-19 vaccine booster candidates against the Omicron   variant Company announcing a new variant-specific vaccine candidate against Omicron   (mRNA-1273.529)...

Authorization includes the use of Moderna’s booster dose following primary vaccination with other authorized or approved COVID-19 vaccines CAMBRIDGE, Mass. –(BUSINESS WIRE)–Nov. 19, 2021–...

Moderna has recognized the substantial role that the NIAID has played in helping to develop Moderna’s COVID-19 vaccine by including NIAID scientists as co-inventors...

CAMBRIDGE, Mass. –(BUSINESS WIRE)–Oct. 31, 2021– Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today provided an update...

Results are the first from pivotal study in children aged six years to under 12 years Two 50 μg doses of mRNA-1273 were generally...

  • “Safety data continues to be monitored by an independent safety monitoring committee. All participants will be monitored for 12 months after their 2nd injection to assess long-term protection and safety. These data are subject to change” Experimental eh? https://t.co/fcvFTFnLtq - view on twitter

Results are the first from pivotal study in children aged six years to under 12 years Two 50 μg doses of mRNA-1273 were generally...

  • … As I’m breaking down the Pfizer data on IG … Moderna Announces Positive Top Line Data from Phase 2/3 Study of COVID-19 Vaccine in Children 6 to 11 Years of Age. What a time. (All jokes. No competition over here.) https://t.co/fbLiofVnDK - view on twitter

CAMBRIDGE, Mass. –(BUSINESS WIRE)–Sep. 16, 2021– Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced Health Canada...

mRNA-6231 is Moderna’s first autoimmune therapeutic candidate to enter the clinic Moderna now has clinical programs in five different therapeutic areas CAMBRIDGE, Mass. –(BUSINESS...

Final blinded analysis of Phase 3 COVE study of the Moderna COVID-19 vaccine shows 93% efficacy; efficacy remains durable through six months after second...

Final blinded analysis of Phase 3 COVE study of the Moderna COVID-19 vaccine shows 93% efficacy; efficacy remains durable through six months after second...